Navigation Links
Bacterial Identification System Differentiates Virulent “Big 6” E. Coli Strains in Five Hours
Date:6/5/2013

Woburn, MA (PRWEB) June 05, 2013

PathoGenetix, Inc., developer of an automated system for rapid bacterial identification, has presented new research demonstrating the use of Genome Sequence Scanning™ (GSS™) to identify and differentiate virulent Shiga toxin-producing E. coli (STEC) strains directly from enriched food samples in five hours. The results, which were detailed in a poster presented at the Association of Public Health Laboratories (APHL) Annual Meeting on Sunday, have significant implications for food producers required to test their products for pathogens with certain virulence characteristics, and for public health agencies needing to quickly identify and find the source of foodborne illness outbreaks.

The research tested representative strains of the pathogenic “Big 6” STECs, which contained the stx and eae virulence genes, as well as non-STEC Big 6 E. coli, on PathoGenetix’s Genome Sequence Scanning system. GSS successfully identified and differentiated each serovar of the Big 6 STEC E. coli. In addition, preliminary data showed the potential to differentiate Big 6 STECs from Big 6 E. coli of the same serotype that do not possess the stx and/or eae virulence genes. The current criteria for determining the presence of a Big 6 pathogen is the identification of the presence of both of these virulence genes in a Big 6 serovar.

The most common STEC serotype is O157:H7, which food producers have been testing for since 1994. Last year, the U.S. Department of Agriculture Food Safety and Inspection Service (USDA-FSIS) added six additional pathogenic E. coli serotypes (O26, O45, O103, O111, O121 and O145) to its list of food adulterants that it requires meat producers to test for in certain beef products.

Current screening methods have a high “false positive” rate for virulence due to the commingling of virulence factors that can be present in an enriched food sample. The ability of GSS to reliably differentiate virulent STECs means that the system could be used as a confirmatory method for Big 6 STEC screening assays, and potentially reduce the loss of product associated with false positive results from current STEC screening tests.

The automated GSS system extracts, scans and analyzes microbial DNA directly from a complex sample to provide bacterial serotype and strain type results in five hours. The bacterial strain information provided by GSS is comparable to pulsed field gel electrophoresis (PFGE), the current standard for pathogen typing in foodborne illness outbreak investigations. Unlike PFGE however, GSS does not require pure culture isolates and thus is compatible with newer pathogen detection methods in use in clinical and food industry laboratories. Genome Sequence Scanning will be commercially available in 2014 as the RESOLUTION™ Microbial Genotyping System.

About PathoGenetix, Inc.

PathoGenetix, Inc. is a commercial-stage developer of an automated system for rapid bacterial identification from complex samples. PathoGenetix is a venture-backed company that has received more than $50 million in technology development funding from the Department of Homeland Security. The core GSS technology isolates and analyzes DNA directly from an enriched biological sample—without the need for a cultured isolate—and provides results in just five hours, days faster than current methods. GSS has broad applicability in food safety, industrial microbiology, and clinical diagnostics and research. The first commercial GSS system will be available in 2014 for use in food safety testing and foodborne illness outbreak investigations. Learn more at http://www.pathogenetix.com.

Read the full story at http://www.prweb.com/releases/APHL/Ecoli_STEC/prweb10802733.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay
2. Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay
3. Cempra Presents Post-Phase 2 Analysis of Solithromycins Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP)
4. Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay
5. Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay
6. PathoGenetix Advances Commercialization of New RESOLUTION Microbial Genotyping System for Rapid Bacterial Serotyping and Strain Typing
7. Synedgen Announces Effective Treatment Against Bacterial Biofilms in Minor Animal Species
8. PathoGenetix and FDA to Evaluate Bacterial Identification System for Use in FDA Public Health and Food Safety Efforts
9. Seeing the Future: How a Revolutionary New Bacterial Screening Device can Predict a Patient’s Future for Tooth Decay
10. Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay
11. Seeing the Future: How a Revolutionary New Bacterial Screening Device can Predict a Patient’s Future for Tooth Decay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... NY (PRWEB) , ... January 19, 2017 , ... FireflySci ... an exponential rate. The tremendous growth is accounted to two main factors. ... table and the expanding network of vendors supplying FireflySci products all around the world. ...
(Date:1/19/2017)... 18, 2017 Acupath Laboratories, Inc., a leading ... of an Executive Committee that will guide the company,s ... John Cucci , a 15-year veteran of the ... Business Development to Chief Sales Officer .  Prior ... in senior sales leadership roles at several leading lab ...
(Date:1/18/2017)... Jan. 18, 2017   Boston Biomedical , an ... to target cancer stemness pathways, will feature data from ... at the 2017 ASCO Gastrointestinal Cancers Symposium, held from ... Napabucasin is an orally-administered investigational agent ... i Cancer stem cells (CSCs) possess the property ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... that Dr. Dante Leven successfully implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation took place ... in Valley Stream, NY. The procedure was an anterior cervical discectomy and fusion ...
Breaking Biology Technology:
(Date:1/13/2017)... 2017 Sandata Technologies, LLC, a leading ... industry, including Electronic Visit Verification™ (EVV™), announced today ... as Senior Vice President of Product Management. ... homecare experience to Sandata, where he will be ... align Sandata,s suite of solutions with the needs ...
(Date:1/11/2017)... NEW BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, ... from Foundation Venture Capital Group, Inc., has been named to the ... Johnson, 27,  was one of 600 people in 20 fields ... only four percent of the 15,000 applicants were selected. ... He is currently a PhD ...
(Date:1/4/2017)...  CES 2017 – Valencell , the leading ... the launch of two new versions of its ... sensor modules that incorporate the best of Valencell,s ... The two new designs include Benchmark BE2.0, a ... Benchmark BW2.0, a 2-LED version of its original ...
Breaking Biology News(10 mins):